Castellana, Marco http://orcid.org/0000-0002-1175-8998
Cignarelli, Angelo http://orcid.org/0000-0001-6477-9031
Brescia, Francesco
Perrini, Sebastio http://orcid.org/0000-0002-2728-7721
Natalicchio, Annalisa http://orcid.org/0000-0002-6131-7517
Laviola, Luigi http://orcid.org/0000-0001-8860-5845
Giorgino, Francesco http://orcid.org/0000-0001-7372-2678
Article History
Received: 31 May 2019
Accepted: 11 November 2019
First Online: 18 December 2019
Competing interests
: M.C., A.C., F.B., S.P. and A.N.: none. For L.L.: Advisory Boards: AstraZeneca, Eli Lilly, Novo Nordisk, Roche Diabetes Care, Sanofi. For F.G.: Advisory Boards: AstraZeneca, Eli Lilly, Novo Nordisk, Roche Diabetes Care; Consultant: Boehringer Ingelheim, Lifescan, Merck Sharp & Dohme, Sanofi, AstraZeneca, Medimmune, Roche Diabetes Care; Research Support: Eli Lilly; Lifescan, Takeda.